GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The company is headquartered in San Francisco, California and currently employs 1 full-time employees. The company went IPO on 2013-10-22. The firm is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The firm also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
Follow-Up Questions
Who is the CEO of GT Biopharma Inc?
Mr. Michael Breen is the Executive Chairman of the Board of GT Biopharma Inc, joining the firm since 2021.
What is the price performance of GTBP stock?
The current price of GTBP is $0.6066, it has decreased 2.64% in the last trading day.
What are the primary business themes or industries for GT Biopharma Inc?
GT Biopharma Inc belongs to Biotechnology industry and the sector is Health Care
What is GT Biopharma Inc market cap?
GT Biopharma Inc's current market cap is $2.1M
Is GT Biopharma Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for GT Biopharma Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
